G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
June 13, 2022 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
logo.png
Verano Founder and Chief Executive Officer George Archos and Chief Operating Officer Darren Weiss Share Celebratory Comments on New Jersey Cannabis Regulatory Commission’s Approval of Personal Use Cannabis Sales
April 11, 2022 16:21 ET | Verano Holdings Corp.
CHICAGO, April 11, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today shared executive commentary...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 08:00 ET | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Biosplice logo_final RGB 300 dpi_white background.png
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
November 17, 2021 09:15 ET | Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
October 29, 2020 16:36 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
September 28, 2020 08:45 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
Bombardier Aéronautique - Business Aircraft.jpg
Bombardier étend le soutien mondial à la clientèle par des capacités accrues de réparations structurelles
July 27, 2020 10:19 ET | Bombardier Avions d’affaires
Les capacités accrues procurent aux clients un soutien inégalé et plus de raison de ramener leurs avions dans les centres de services de Bombardier Le Centre de réponse à la clientèle (CRC) de...
Bombardier Aéronautique - Business Aircraft.jpg
Bombardier Expands Worldwide Customer Support with Enhanced Structural Repair Capabilities
July 27, 2020 10:19 ET | Bombardier Business Aircraft
Extended capabilities provide customers with unparalleled support and more reasons to bring their jets home to Bombardier Bombardier’s Customer Response Center (CRC) remains the single point of...
Never Too Young Surv
Never Too Young Survey Report Shows Young-Onset Colorectal Cancer Continues to be Overlooked in Exam Rooms
June 04, 2020 11:27 ET | Colorectal Cancer Alliance
Washington, D.C., June 04, 2020 (GLOBE NEWSWIRE) -- Today, during Young Survivors Week, national leading non-profit Colorectal Cancer Alliance released findings from its latest survey of young-onset...
Updated: Expert Stak
Updated: Expert Stakeholder Panel Focuses on Colorectal Cancer Screening in the COVID-19 Era
May 15, 2020 15:27 ET | Colorectal Cancer Alliance
Washington, D.C., May 15, 2020 (GLOBE NEWSWIRE) -- COVID-19 has produced far-reaching and significant health impacts, including a drastic reduction in all cancer screenings. In response, national...